Skip to main content
OpenTrials
Completed

NCT Number: NCT02348073

Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy

Our project aims to develop a new therapeutic approach in epilepsy-associated attention disorders in children, through evaluation of the clinical impact of dietary n-3 fatty acids, containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) conjugated to a phospholipid vector. The primary objective is to evaluate the efficacy of a PUFA supplementation (PS-Omega 3), after 12 weeks of treatment, on attention disorders in children with epilepsy. Secondary objectives include:

* To evaluate the impact of a supplementation of PS-Omega 3 on quality of life. * To evaluate the impact of a supplementation of PS-Omega 3 on serum and erythrocyte lipid profiles. * To assess the tolerance of a supplementation of PS-Omega 3. * To assess the impact of a supplementation of PS-Omega 3 on the frequency of seizures. * To describe the impact of a supplementation of PS-Omega 3, at 24 weeks,

1. on attention disorders in children with epilepsy, 2. on quality of life, 3. and on serum and erythrocyte lipid profiles. This study will recruit 272 subjects aged 6- 16 years, suffering from epilepsy (any type) and attention deficit hyperactivity disorder (ADHD) (inattentive or combined type) according to DSM V criteria in 12 clinical sites in France.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Attention Deficit Disorder With Hyperactivity ADHD Inattention or Mixed Type Attention Deficit and Disruptive Behavior Disorders Brain Diseases Central Nervous System Diseases Child Epilepsy Mental Disorders Nervous System Diseases Neurodevelopmental Disorders

Age range

6 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU de Amiens, Amiens, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 6 to 15 years and 11 months.
  • Children of either sex (male/female) suffering from epilepsy regardless of syndrome classification.
  • Subjects on a stable dose of antiepileptic drugs (AED) for at least one month prior to inclusion and subjects for whom no change is considered a priori for the three months following the inclusion.
  • Diagnosis of ADHD inattention or mixed type according to the DSM V criteria.
  • Subjects must agree to study participation and their parents/legal guardian must provide written inform consent prior to participation in the study.

Exclusion criteria

  • Subjects less than 6 years or older than 16 years old
  • AED not stable for at least one month and/or a change in AED is expected in the three months following inclusion.
  • Diagnosis of ADHD hyperactivity type exclusive according to DSM V criteria.
  • Mental retardation defined by a score < 70 on the verbal comprehension and perceptual reasoning Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV), performed within 18 months prior to inclusion or at V1.
  • Diagnosis of a psychiatric comorbidity other than ADHD according to the DSM V criteria, including: pervasive developmental disorders including autism disorders; bipolar disordersand psychotic disorders.
  • Children suffering from diabetes, any type.
  • Use of psychoactive drugs in ADHD within the previous month: Methylphenidate, Amphetamine, Atomoxetine, Modafinil and Antidepressants whatever the class.
  • Use of dietary supplementation, other than vitamins, within the last 3 months.
  • Use of ketogenic diet within the last 3 months.
  • Allergy to fish or other sea products.
  • Soy allergy.
  • Absence of coverage by social security.

Treatment and study plan

Vayarin®, supplementation of n-3 PUFA

Drug

Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.

At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product.

Placebo

Drug

Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.

Primary outcomes

  1. Reduction of the ADHD-rating scale IV inattentive subscore in subjects assigned to supplementation of PS-Omega 3 in comparison with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    The ADHD Rating Scale-IV quantifies each of the 18 symptoms of ADHD on a 0 to 3 scale, with a maximum score of 54 points. Nine of the 18 items score for inattention while the nine others assess hyperactivity with a maximum of 27 points each. The discriminative value of these two subscales was validated, allowing their individual use.

Secondary outcomes

  1. Reduction of the ADHD Rating Scale-IV total score in the PS-Omega 3 group compared with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    The ADHD Rating Scale-IV quantifies each of the 18 symptoms of ADHD on a 0 to 3 scale, with a maximum score of 54 points.

  2. Reduction of TOVA total score in the PS-Omega 3 group compared with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    The TOVA (Test of Variables of Attention) is a computerized tool assessing the capacity of attention and impulse control. This test has been validated as a diagnostic tool in ADHD.

  3. Proportion of subjects with a normalized TOVA score in the PS-Omega 3 group compared with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    The TOVA (Test of Variables of Attention) is a computerized tool assessing the capacity of attention and impulse control. This test has been validated as a diagnostic tool in ADHD.

  4. Change in quality of life score in the PS-Omega 3 group compared with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    Quality of life assessed by the EFIQUACEE questionnaire (Echelle Française d'Impact et de Qualité de Vie Chez l'Enfant atteint d'Epilepsie).

    The EFIQUACEE questionnaire is a unique quality of life scale for children suffering from epilepsy. It is validated in French language.

  5. Evolution of plasma lipid profiles in subjects assigned to supplementation of PS-Omega 3 in comparison with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    Plasma levels before and after 12 weeks of treatment: total lipid mass ; total phospholipids ; individual phospholipids including: lysophosphatidylcholin, phosphatidylcholin, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, lysophosphatidylethanolamine ; total triglycerides ; fatty acids profiles in phospholipids; fatty acids profiles in triglycerides ; fatty acids profiles in cholesterol esters.

  6. Evolution of eythrocytes lipid profiles in subjects assigned to supplementation of PS-Omega 3 in comparison with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

    Quantification of, in erythrocyte membrane, before and after 12 weeks of treatment: total lipid mass ; total phospholipids ; individual phospholipids including: lysophosphatidylcholin, phosphatidylcholin, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, lysophosphatidylethanolamine ; total triglycerides ; fatty acids profiles in phospholipids; fatty acids profiles in triglycerides ; fatty acids profiles in cholesterol esters.

  7. Tolerance of a supplementation of PS-Omega 3.

    Time frame: 36 weeks

    Tolerance analysis of the supplementation of PS-Omega 3: interrogatoire, phone calls, clinical examinations, adverse events reported throughout the study.

  8. Number of subjects with a reduction in the frequency of seizures ≥ 50%, in the PS-Omega 3 group compared with the placebo group after 12 weeks of treatment.

    Time frame: 12 weeks

  9. After 24 weeks of treatment, description of the total score of ADHD Rating Scale.

    Time frame: 24 weeks

  10. After 24 weeks of treatment, description of the total score of TOVA.

    Time frame: 24 weeks

  11. After 24 weeks of treatment, proportion of subjects with a normalized TOVA score.

    Time frame: 24 weeks

  12. After 24 weeks of treatment, change in quality of life score (EFIQUACEE questionnaire).

    Time frame: 24 weeks

  13. After 24 weeks of treatment, plasma lipid levels before and after treatment.

    Time frame: 24 weeks

    Plasma levels before and after 24 weeks of treatment: total lipid mass ; total phospholipids ; individual phospholipids including: lysophosphatidylcholin, phosphatidylcholin, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, lysophosphatidylethanolamine ; total triglycerides ; fatty acids profiles in phospholipids; fatty acids profiles in triglycerides ; fatty acids profiles in cholesterol esters.

  14. After 24 weeks of treatment, erythrocyte lipid levels before and after treatment.

    Time frame: 24 weeks

    Quantification of, in erythrocyte membrane, before and after 24 weeks of treatment: total lipid mass ; total phospholipids ; individual phospholipids including: lysophosphatidylcholin, phosphatidylcholin, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, lysophosphatidylethanolamine ; total triglycerides ; fatty acids profiles in phospholipids; fatty acids profiles in triglycerides ; fatty acids profiles in cholesterol esters.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Efficacy of Phosphatidylserine Enriched With Polyunsaturated n-3 Fatty Acid Supplementation on Attention Deficit Disorders in Children With Epilepsy. A Randomized Double-blind Placebo-controlled Trial

Acronym: AGPIn3

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Jan 28, 2015
Registry last updated
Aug 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.